Core Points - Nicox SA announced an extension of the PACEO equity line of financing with Vester Finance, allowing for an additional maximum of 5,000,000 shares, representing 6.43% of the currently issued share capital [1][3] - The company estimates it is financed into Q3 2026 based on current cash and debt positions, excluding proceeds from the new financing [2] - The total gross proceeds from the additional shares could potentially reach €3.1 million at the current share price [3] Financing Details - The financing agreement allows Vester Finance to subscribe for up to 5,000,000 additional shares under the same terms as previously announced [3] - A shareholder holding 1.00% of Nicox's capital before the transaction would see their stake reduced to 0.94% if the full extension is utilized [3] - The agreement can be terminated by the company at any time without penalty [3] Corporate Governance - The transaction was authorized by the CEO based on a delegation from the Board of Directors [4] - No prospectus is required to be submitted to the Autorité des marchés financiers (AMF) for this transaction [4] Shareholder Information - Vester Finance holds approximately 4% of Nicox's share capital and may sell shares over varying timeframes [5] - The company will announce the number of shares issued under this transaction on its website [6] Company Overview - Nicox SA is focused on developing innovative ophthalmology solutions, with its lead program being NCX 470, aimed at lowering intraocular pressure in glaucoma patients [8] - The company also has a preclinical research program on NCX 1728 and generates revenue from products like VYZULTA® and ZERVIATE® [8] - Nicox is listed on Euronext Growth Paris and is part of the CAC Healthcare index [9]

Core Viewpoint - Abcourt Mines Inc. is initiating a non-brokered private placement of a secured convertible debenture to raise gross proceeds of $3,000,000, alongside a secured financing facility of $8 million and a non-brokered equity financing of $1,000,000, aimed at restarting the Sleeping Giant mine and mill [1][6][11][14]. Debenture Offering - The debenture will have an interest rate of SOFR plus 10% per annum and will mature in four years [2] - The principal amount can be converted into common shares at a price of $0.05 per share in the first year and $0.10 per share in subsequent years [2] - The debenture will be purchased by François Mestrallet, a director of the Corporation, constituting a related party transaction [3] - The Corporation will rely on exemptions from formal valuation and minority shareholder approval requirements as the transaction does not exceed 25% of its market capitalization [4] Financing Facility - The Corporation plans to close a secured financing facility with Nebari Natural Resources Credit Fund II, LP for $8 million, with an interest rate of SOFR plus 12% and a term of 36 months [6] - The Corporation has the option to prepay the outstanding principal amount after 365 days, subject to a minimum prepayment of $1,000,000 [7] - The Lender will receive 87,040,000 warrants, each exercisable for one common share at an exercise price of $0.0625 for 36 months [8] Equity Financing - The Corporation intends to close a tranche of non-brokered equity financing for gross proceeds of $1,000,000, selling units at a price of $0.05 per unit [11] - Each unit will consist of one common share and one common share purchase warrant, with the warrant exercisable at $0.08 for 36 months [12] - If the trading price of common shares exceeds $0.12 for 20 consecutive trading days, the Corporation may accelerate the expiry date of the unit warrants [13] Use of Proceeds - The net proceeds from the debenture offering, financing facility, and private placement will be used to restart the Sleeping Giant mine and mill, repay outstanding payables, and for general corporate purposes [14]